PRECISION ONCOLOGY • PHASE 3 HUMAN EVIDENCE • OCTOBER 27, 2026
New Targeted Therapy Extends Survival in Advanced Endometrial Cancer
Evidence classification: Randomized Phase 3 clinical evidence of disease-specific survival extension, not a treatment that reverses biological aging.
The trial
The international TroFuse-005 study randomized 776 patients with advanced or recurrent endometrial cancer whose disease had progressed after platinum-based chemotherapy and immunotherapy. Researchers compared investigational sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate targeting TROP2, against standard chemotherapy.
Clinical outcomes
| Outcome | Sac-TMT | Standard chemotherapy |
|---|---|---|
| Median overall survival | 19.0 months | 12.1 months |
| Median progression-free survival | 7.2 months | 3.9 months |
| Objective tumor response | 35.1% | 17.3% |
| Alive at 12 months | 63.4% | 50.8% |
The reported overall-survival hazard ratio was 0.68 (95% CI 0.55–0.84), a 32% relative reduction in the hazard of death during follow-up. The 6.9-month difference in median survival is a group-level trial result, not a prediction for any individual patient. Both overall survival and progression-free survival met statistical significance.
How it works
Sac-TMT uses an antibody to recognize TROP2-expressing cells and deliver a cytotoxic payload. This is targeted chemotherapy delivery, not generalized immune rejuvenation or a senolytic treatment.
Safety and remaining questions
Grade 3 or higher treatment-related adverse events were reported in 54.4% receiving sac-TMT versus 41.4% receiving chemotherapy. Reported toxicities included anemia, stomatitis and ocular effects. Longer follow-up and careful patient selection are needed. As of this report, the treatment remained investigational for this indication, with an FDA review decision expected in 2027.
What this means for healthy longevity
For eligible patients facing advanced endometrial cancer, a substantial improvement in actual survival is meaningful. But extending life in a serious illness is not the same as slowing normal aging: these results do not establish longer lifespan in healthy people, reversal of senescence, or systemic rejuvenation.
Sources
ESMO Congress 2026: TroFuse-005 Phase 3 presentation
The Lancet: TroFuse-005 Phase 3 publication (October 2026)
ClinicalTrials.gov: TroFuse-005 trial registry search
Educational summary, not individualized medical advice. Added October 27, 2026. Figures should be checked against the final peer-reviewed paper before clinical use.